Ipravent Rotacaps Capsules

Ipravent Rotacaps Capsules, the effective medicine with the ability to expand the airways and is therefore used in conditions with reversible constriction respiratory tract.

How to use Ipravent Rotacaps Capsule

Take this medicine in the dose and duration as advised by your doctor. Do not chew, crush or break it.

Expert Advice

• The correct use of the Rotahaler is significant for successful treatment.
• Do not take Rotacaps orally.
• It should be taken at the same time each day.
• Your doctor may monitor your blood potassium level regularly while taking this medication.

IF YOU HAVE TAKEN MULTIPLE DOSES OF MEDICINE?

If you use more IPRAVENT ROPACAPS than you should ask your doctor for advice or pharmacist.

In order to attain maximum client satisfaction, we check the product quality on several counts at several stages. We are a noteworthy name, engaged in offering qualitative lot of products that are the perfect outcome of premium material and modern work methods. Also, the material is sourced from the trusted places after complete quality checking.

Details :

• Ipratropium bromide is a bronchodilator that dilates (enlarges) airways (bronchi) in the lungs. It is used in treating, symptoms of asthma, colds, allergies, and chronic obstructive pulmonary disease (COPD) due to emphysema or chronic bronchitis. Ipratropium blocks the effect of acetylcholine on airways (bronchi) and nasal passages.

• Acetylcholine is a chemical that nerves use to communicate with muscle cells. In asthma and chronic obstructive pulmonary disease, cholinergic nerves going to the lungs cause narrowing of the airways by stimulating muscles surrounding the airways to contract. The "anti-cholinergic" effect of ipratropium blocks the effect of cholinergic nerves, causing the muscles to relax and airways to dilate. Mucus glands in the nose also are controlled by nerves that use acetylcholine to communicate.

• By blocking acetylcholine, ipratropium helps relieve symptoms of allergies and the common cold by preventing secretion of mucus by mucus glands in the nose. When inhaled, ipratropium travels directly to airways, and very little is absorbed into the body. The FDA approved ipratropium in October 1995.